Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Jing HAN
Jing HAN



Alphamab Oncology

韩净先生目前供职于康宁杰瑞担任首席商务官职位,主要负责公司商业化运营,上市前临床协调部工作以及外包产品(石药先声)商业化合作。在此之前,韩净先生担任嘉和生物高级副总裁职位,负责组建营销团队及上市前各项商业化工作。在担任上海君实生物副总经理期间,建立营销部搭建团队至550人,制定以大医学概念为前提的市场销售策略,2018年在比竞争对手少一半人员的情况下完成7.74亿销售(10个月),费用比仅48%(信达76%,百济2020年上市第一年90%以上);开展肺肝食管淋巴瘤等癌肿ISS项目80余项,部分如肝内胆管癌(PD-1+仑伐+Gemox,40%,上海中山医院樊嘉周俭)ORR达90%,后正式立项三期三臂临床,二期数据列入2021年CSCO胆管癌治疗指南。作为临床医生出生的韩净先生也曾在罗氏制药、拜耳医药、 阿斯利康、勃林格殷格翰、默沙东等大型跨国药企均有过从业经验。